Roles of Glycogen Synthase Kinase 3 in Alzheimer’s Disease
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Evidence from basic molecular biology has noted a critical role of GSK-3 in Alzheimer's disease (AD) pathogenesis such as beta-amyloid (Aβ) production and accumulation, the formation of neurofibrillary tangle (NFT), and neuronal degeneration. Aβ generation and deposition represents a key feature and is generated from APP by the sequential actions of two proteolytic enzymes: β-secretase and γ-secretase. GSK-3 could play a critical role in Aβ production via enhancing β-secretase activity. GSK-3 not only modulates APP processing in the process of Aβ generation, but regulates Aβ production by interfering with APP cleavage at the γ-secretase complex step since the APP and PS1 (a component of γ- secretase complex) are substrates of GSK-3 as well. GSK-3 may downregulate α-secretase through inhibiting PKC and ADAMs activity which are the substrates of GSK-3 contributing to Aβ production. Meanwhile, Aβ accumulation can induce GSK-3 activation through Aβ-mediated neuroinflammation and oxidative stress. Considering that active GSK-3 and some common GSK-3-shared factors induce the hyperphosphorylation of tau and neurofibrillary lesions, GSK-3 is a possible linking between amyloid plaques and NFT pathology. Additionally, GSK-3 could disrupt acetylcholine activity, and accelerate axon degeneration and failures in axonal transport, and lead to cognitive impairment in AD. Preclinical and clinical studies have supported that GSK-3β inhibitors could be useful in the treatment of AD. Consequently, an effective measure to inhibit GSK-3 activity may be a very attractive drug target in AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GSK-3: tricks of the trade for a multi-tasking kinase
Doble, B. W., & Woodgett, J. R. (2003) · Journal of Cell Science · doi:10.1242/jcs.00384 · Cited by 2,084
Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis
Whitehouse, P. J., Price, D. L., Clark, A. W., Coyle, J. T., & DeLong, M. R. (1981) · Annals of Neurology · doi:10.1002/ana.410100203 · Cited by 1,736
Terry, A. V., & Buccafusco, J. J. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.041616 · Cited by 1,159
The cell biology of synaptic plasticity: AMPA receptor trafficking
Shepherd, J. D., & Huganir, R. L. (2007) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.23.090506.123516 · Cited by 978 · cited 1×
“The disturbance of membrane trafficking could result in various disorders [96].”
BackgroundAge-related myelin breakdown: a developmental model of cognitive decline and Alzheimer’s disease
Bartzokis, G. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.03.001 · Cited by 968 · cited 3×
“The breakdown of myelin promotes the buildup of toxic A fibrils that deposit in the brain and eventually become amyloid plaques [207, 210].”
BackgroundDe Felice, F. G., Velasco, P. T., Lambert, M. P., Viola, K., Fernandez, S. J., Ferreira, S. T., & Klein, W. L. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m607483200 · Cited by 882 · cited 1×
“Accumulation of A leads to both plaque formation and to tau hyperphosphorylation [161-164].”
BackgroundInflammatory processes in Alzheimer's disease
Heneka, M. T., & O'Banion, M. K. (2007) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.11.017 · Cited by 782
Glycogen synthase kinase-3 (GSK3): Inflammation, diseases, and therapeutics
Jope, R. S., Yuskaitis, C. J., & Beurel, E. (2007) · Neurochemical Research · doi:10.1007/s11064-006-9128-5 · Cited by 774 · cited 2×
“Both A deposition and GSK-3 promote the production of inflammatory molecules and oxidative stress in brain, which together make A a powerful regulator of inflammation and oxidative stress [119].”
BackgroundAlzheimer's disease as homeostatic responses to age-related myelin breakdown
Bartzokis, G. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.08.007 · Cited by 546
Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies
Brunden, K. R., Trojanowski, J. Q., & Lee, V. M.-Y. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2959 · Cited by 440
The axo-axonic interneuron in the cerebral cortex of the rat, cat and monkey
Somogyi, P., Freund, T. F., & Cowey, A. (1982) · Neuroscience · doi:10.1016/0306-4522(82)90086-0 · Cited by 392 · cited 1×
“Some axons are covered with a fatty substance called myelin that acts as an insulator [193, 194].”
BackgroundA novel GSK-3β inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo
Serenó, L., Coma, M., Rodríguez, M., Sánchez-Ferrer, P., Sánchez, M. B., Gich, I., Agulló, J. M., Pérez, M., Avila, J., Guardia-Laguarta, C., et al. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.05.025 · Cited by 368
GSK3: a possible link between beta amyloid peptide and tau protein
Hernández, F., Gómez de Barreda, E., Fuster-Matanzo, A., Lucas, J. J., & Avila, J. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2009.09.011 · Cited by 327 · cited 2×
“GSK-3 promotes inflammation in several prevalent diseases which involve inflammation, including mood disorders, AD, diabetes, and cancer [26, 70, 117, 118].”
BackgroundBiochemistry of Tau in Alzheimer’s disease and related neurological disorders
Sergeant, N., Bretteville, A., Hamdane, M., Caillet-Boudin, M.-L., Grognet, P., Bombois, S., Blum, D., Delacourte, A., Pasquier, F., Vanmechelen, E., et al. (2008) · Expert Review of Proteomics · doi:10.1586/14789450.5.2.207 · Cited by 300 · cited 1×
“The hyperphosphorylation of the tau and abrogation of its microtubule is detrimental in maintaining axon structure and the function of synapses [199].”
BackgroundTakashima, A., Honda, T., Yasutake, K., Michel, G., Murayama, O., Murayama, M., Ishiguro, K., & Yamaguchi, H. (1998) · Neuroscience Research · doi:10.1016/s0168-0102(98)00061-3 · Cited by 287
GSK-3β inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila
Mudher, A., Shepherd, D., Newman, T. A., Mildren, P., Jukes, J. P., Squire, A., Mears, A., Berg, S., MacKay, D., Asuni, A. A., et al. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001483 · Cited by 265 · cited 2×
“Tau protein kinase I/glycogen synthase kinase-3 (TPK-I/GSK-3 ) may result in an impairment of axonal transport and cytoplasmic accumulation of APP [215].”
BackgroundRole of the β‐amyloid protein in Alzheimer's disease
Sisodia, S. S., & Price, D. L. (1995) · The FASEB Journal · doi:10.1096/fasebj.9.5.7896005 · Cited by 262
Severely dystrophic axons at amyloid plaques remain continuous and connected to viable cell bodies
Adalbert, R., Nogradi, A., Babetto, E., Janeckova, L., Walker, S. A., Kerschensteiner, M., Misgeld, T., & Coleman, M. P. (2009) · Brain · doi:10.1093/brain/awn312 · Cited by 177 · cited 2×
“Activation of GSK-3 can cause memory deficits as seen in AD and inhibit long term potentiation with synapse-associated impairments [201, 226, 227].”
BackgroundSofola, O., Kerr, F., Rogers, I., Killick, R., Augustin, H., Gandy, C., Allen, M. J., Hardy, J., Lovestone, S., & Partridge, L. (2010) · PLoS Genetics · doi:10.1371/journal.pgen.1001087 · Cited by 174
Reactivating Kinase/p38 Phosphorylates τ Protein In Vitro
Reynolds, C. H., Nebreda, A. R., Gibb, G. M., Utton, M. A., & Anderton, B. H. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69010191.x · Cited by 161
Anthony, I. C., Norrby, K. E., Dingwall, T., Carnie, F. W., Millar, T., Arango, J. C., Robertson, R., & Bell, J. E. (2010) · Brain · doi:10.1093/brain/awq263 · Cited by 156 · cited 1×
“GSK-3 is prominently present in neuronal cell bodies and their processes and colocalizes with neurofibrillary changes in AD brain [126, 127].”
BackgroundWhy is the amyloid beta peptide of Alzheimer’s disease neurotoxic?
Rauk, A. (2008) · Dalton Transactions · doi:10.1039/b718601k · Cited by 139
Plaschke, K., Kopitz, J., Siegelin, M., Schliebs, R., Salkovic-Petrisic, M., Riederer, P., & Hoyer, S. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-1270 · Cited by 118 · cited 1×
“The phosphatidylinositol 3-kinase-protein kinase B (PI3K/AKT) pathway is involved in insulin signaling transduction, with the downstream involvement of GSK3[169].”
BackgroundAbad, M. A., Enguita, M., DeGregorio-Rocasolano, N., Ferrer, I., & Trullas, R. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.0575-06.2006 · Cited by 102
GSK-3β Directly Phosphorylates and Activates MARK2/PAR-1
Kosuga, S., Tashiro, E., Kajioka, T., Ueki, M., Shimizu, Y., & Imoto, M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m507941200 · Cited by 57 · cited 1×
“GSK-3 regulates multiple cellular processes, and its dysregulation is implicated in the pathogenesis of diverse diseases [61].”
BackgroundLatimer, D. A., Gallo, J.-M., Lovestone, S., Miller, C. C. J., Hugh Reynolds, C., Marquardt, B., Stabel, S., Woodgett, J. R., & Anderton, B. H. (1995) · FEBS Letters · doi:10.1016/0014-5793(95)00434-b · Cited by 48
Expression of the Anti-amyloidogenic Secretase ADAM10 Is Suppressed by Its 5′-Untranslated Region
Lammich, S., Buell, D., Zilow, S., Ludwig, A.-K., Nuscher, B., Lichtenthaler, S. F., Prinzen, C., Fahrenholz, F., & Haass, C. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.110742 · Cited by 48
Unraveling the Molecular Mechanisms Behind the Metabolic Basis of Sporadic Alzheimer's Disease
Erol, A. (2008) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-1047 · Cited by 30
Cited by
Agrawal, M., Saraf, S., Saraf, S., Antimisiaris, S. G., Chougule, M. B., Shoyele, S. A., & Alexander, A. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.05.011 · Cited by 630
Glycogen synthase kinase-3 signaling in Alzheimer's disease
Lauretti, E., Dincer, O., & Praticò, D. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2020.118664 · Cited by 615
GSK-3β, a pivotal kinase in Alzheimer disease
Llorens-MarÃtin, M., Jurado, J., Hernández, F., & Ãvila, J. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00046 · Cited by 451
GSK-3 and tau: a key duet in Alzheimer’s disease
Sayas, C. L., & Ávila, J. (2021) · Cells · doi:10.3390/cells10040721 · Cited by 314
A walk through tau therapeutic strategies
Jadhav, S., Avila, J., Schöll, M., Kovacs, G. G., Kövari, E., Skrabana, R., Evans, L. D., Kontsekova, E., Malawska, B., de Silva, R., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0664-z · Cited by 290
Metadata
- Authors
- Cai, Z., Zhao, Y., & Zhao, B.
- Venue
- Current Alzheimer Research
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2012-08-01
- Volume
- 9
- Issue
- 7
- Pages
- 864-879
- ISSN
- 1567-2050 (ISSN-L)
- OpenAlex
- W2110353852
- Cited by
- 145
- References
- 28
- FWCI
- 4.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.